Attached files

                   TECHNE CORPORATION ANNOUNCES ACQUISITION

Minneapolis/April 4, 2011/--Techne Corporation (NASDAQ: TECH) announced today
that as of April 1, 2011, its R&D Systems subsidiary has acquired the assets
of Boston Biochem, Inc., a leading developer and manufacturer of innovative
ubiquitin-related research products.  These products provide biomedical
researchers the tools that facilitate and accelerate basic research and drug
discovery efforts. R&D Systems Europe simultaneously acquired the assets of
Boston Biochem Limited, a United Kingdom based company that serves as the
European markets distributor of the Boston Biochem, Inc. products.  R&D
Systems is a leading developer and manufacturer of purified cytokines
(proteins), antibodies and assay kits which are sold to biomedical
researchers and clinical research laboratories.

Boston Biochem was founded in 1997 and currently offers over 800 ubiquitin-
related products. The Ubiquitin Proteasome Pathway is the principal system
for protein degradation and signaling in eukaryotic cells.  Ubiquitination
also affects proteasome-independent events such as protein localization,
activity and function.  These pathways are central to the regulation of
almost all cellullar processes.  Ubiquitin and related pathways are
associated with the regulation of numerous disease states including multiple
cancers, diabetes, Parkinson', Alzheimer's, cystic fibrosis, Angelman's
syndrome, Liddle syndrome and Wilson's disease.

The acquisitions will enhance and supplement the depth and breadth of R&D
Systems' product offering and will augment its ability to serve research
scientists, as well as leverage its marketing, sales and distribution
capabilities with this important product class.

Boston Biochem, Inc. and Boston Biochem Limited had combined product sales of
about $2.5 million in calendar 2010 and, therefore, the acquisitions will not
have a material effect on Techne Corporation's fourth quarter fiscal year
2011 or fiscal 2012 sales.  The acquisitions are expected to be slightly
dilutive (less than $0.02/share) to Techne Corporation's fiscal year ending
June 30, 2012 net earnings due to the impact of acquisition accounting.  The
Boston Biochem assets were acquired for cash.

Tom Oland, President and CEO of Techne Corporation, said "The interest in
ubiquitin and ubiquitin-related research is rapidly expanding, as evidenced
by the increasing number of ubiquitin-related scientific publications.  I
strongly believe there is significant potential synergy associated with these
acquisitions and our current business.  Boston Biochem has earned a
reputation as a premier developer of high quality reagents for research
scientists and they have established themselves as a key supplier to those
conducting ubiquitin-related research.  With these acquisitions we will be
able to expand our reputation for offering high quality research reagents
throughout the world."

Boston Biochem founder and President, Francesco Melandri, added "The
transaction with Techne Corporation is strategically ideal for Boston
Biochem.  The importance of ubiquitin in the regulation of disease continues
to grow and with this comes large and continuing increased in demand for
discovery tools worldwide.  Techne's commitment to ubiquitin-related research
coupled to support of Boston Biochem's development capabilities will
significantly accelerate our ability to expand and meet these research needs,
for both basic and drug discovery.  I have every confidence that this
strategy will allow the Boston Biochem brand to maintain its leadership and
reputation worldwide in this critical area of study well into the future."

Mr. Melandri will continue to lead the ongoing product development of
ubiquitin-related products and will remain active in promoting and enhancing
relationships with customers and the ubiquitin research communities.


Our press releases may contain forward-looking statements within the meaning
of the Private Litigation Reform Act.  Forward-looking statements contained
in this press release relate our expectations as to the strategic and
financial impact of the Boston Biochem transaction.  Forward-looking
statements involve risks and uncertainties that may affect the actual results
of operations. The following important factors, among others, have affected
and, in the future, could affect the Company's actual results: the
integration of the Boston Biochem operations, the introduction and acceptance
of new biotechnology and hematology products, the levels and particular
directions of research by the Company's customers, the impact of the growing
number of producers of biotechnology research products and related price
competition, general economic conditions, the retention of hematology OEM and
proficiency survey business, the impact of currency exchange rate
fluctuations, and the costs and results of research and product development
efforts of the Company and of companies in which the Company has invested or
with which it has formed strategic relationships.

For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in our press releases due to
new information or future events.  Investors are cautioned not to place undue
emphasis on these statements.

                    * * * * * * * * * * * * * *
Techne Corporation has two operating subsidiaries: Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific) located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacifc
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits.  R&D China and R&D Europe distribute
biotechnology products.

Contact:
Greg Melsen, Chief Financial Officer
Kathy Backes, Controller
(612) 379-8854